Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-07-12
2011-07-12
Aeder, Sean E (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
Reexamination Certificate
active
07977463
ABSTRACT:
In certain embodiments, this present invention provides polypeptide compositions (e.g., antibodies and antigen binding portions thereof that bind to EphB4), and methods for inhibiting EphB4 activity. In other embodiments, the present invention provides methods and compositions for treating cancer or for treating angiogenesis-associated diseases.
REFERENCES:
patent: 5512591 (1996-04-01), Halperin et al.
patent: 5624899 (1997-04-01), Bennett
patent: 5635177 (1997-06-01), Bennett
patent: 5693762 (1997-12-01), Queen et al.
patent: 5770599 (1998-06-01), Gibson
patent: 5795734 (1998-08-01), Flanagan et al.
patent: 5824303 (1998-10-01), Bartley et al.
patent: 5864020 (1999-01-01), Bennett
patent: 6015711 (2000-01-01), Olson et al.
patent: 6303769 (2001-10-01), Cerretti
patent: 6413730 (2002-07-01), Holland
patent: 6440954 (2002-08-01), Haber et al.
patent: 6479459 (2002-11-01), Cerretti
patent: 6492140 (2002-12-01), Cerretti et al.
patent: 6514497 (2003-02-01), Briskin et al.
patent: 6579683 (2003-06-01), Wang et al.
patent: 6864227 (2005-03-01), Wang et al.
patent: 6887674 (2005-05-01), Wang et al.
patent: 6916625 (2005-07-01), Wang et al.
patent: 2002/0086819 (2002-07-01), Drummond et al.
patent: 2002/0136726 (2002-09-01), Anderson et al.
patent: 2002/0146420 (2002-10-01), Bennett
patent: 2004/0110150 (2004-06-01), Koller et al.
patent: 2004/0234520 (2004-11-01), Aguet et al.
patent: 2004/0247592 (2004-12-01), Roifman et al.
patent: 2005/0049176 (2005-03-01), Kiener et al.
patent: 2005/0084873 (2005-04-01), Krasnoperov et al.
patent: 2005/0164965 (2005-07-01), Reddy et al.
patent: 2005/0187154 (2005-08-01), Kahn et al.
patent: 2005/0204412 (2005-09-01), Wang et al.
patent: 2006/0035328 (2006-02-01), Wang et al.
patent: 2006/0204512 (2006-09-01), Krasnoperov et al.
patent: 2006/0241027 (2006-10-01), Hauser et al.
patent: 2007/0207952 (2007-09-01), Silva et al.
patent: 0 442 724 (1991-08-01), None
patent: 0 633 315 (1995-01-01), None
patent: 0999 278 (2000-05-01), None
patent: WO 93/00425 (1993-01-01), None
patent: WO-93/15201 (1993-08-01), None
patent: WO 94/10202 (1994-05-01), None
patent: WO 94/11020 (1994-05-01), None
patent: WO-95/27061 (1995-10-01), None
patent: WO-96/01839 (1996-01-01), None
patent: WO-96/02645 (1996-02-01), None
patent: WO 96/03043 (1996-02-01), None
patent: WO 96/09384 (1996-03-01), None
patent: WO 96/13518 (1996-05-01), None
patent: WO 96/23000 (1996-08-01), None
patent: WO 96/26958 (1996-09-01), None
patent: WO-96/26958 (1996-09-01), None
patent: WO 96/36713 (1996-11-01), None
patent: WO 97/09427 (1997-03-01), None
patent: WO 97/23629 (1997-07-01), None
patent: WO 97/44453 (1997-11-01), None
patent: WO-98/01548 (1998-01-01), None
patent: WO 98/43960 (1998-10-01), None
patent: WO 98/45331 (1998-10-01), None
patent: WO-98/45708 (1998-10-01), None
patent: WO-99/08696 (1999-02-01), None
patent: WO 99/17796 (1999-04-01), None
patent: WO 99/52541 (1999-10-01), None
patent: WO-00/24413 (2000-05-01), None
patent: WO 00/30673 (2000-06-01), None
patent: WO-00/30673 (2000-06-01), None
patent: WO 01/49743 (2001-07-01), None
patent: WO 01/81377 (2001-11-01), None
patent: WO-02/11785 (2002-02-01), None
patent: WO-02/26827 (2002-04-01), None
patent: WO-02/058538 (2002-08-01), None
patent: WO-02/061055 (2002-08-01), None
patent: WO-02/079382 (2002-10-01), None
patent: WO-02/102854 (2002-12-01), None
patent: WO-02/102972 (2002-12-01), None
patent: WO-02/102973 (2002-12-01), None
patent: WO 03/000113 (2003-01-01), None
patent: WO-03/004057 (2003-01-01), None
patent: WO 03/094859 (2003-11-01), None
patent: WO 2004/014292 (2004-02-01), None
patent: WO 2004/020468 (2004-03-01), None
patent: WO-2004/024773 (2004-03-01), None
patent: WO-2004/080425 (2004-09-01), None
patent: WO 2004/091375 (2004-10-01), None
patent: WO-2005/048917 (2005-06-01), None
patent: WO 2005/051307 (2005-06-01), None
patent: WO 2005/090406 (2005-09-01), None
Stephenson et al (BMC Molecular Biology, Dec. 21, 2001, 2(15): 1-9).
Santa Cruz Biotechnology Inc datasheet for EphB4(H-200).
Santa Cruz Biotech Inc datasheet for EphB4(H-200).
Miki et al., “Association of Ash/Grb-2 with Dynamin through the Src Homology 3 Domain”, The Journal of Biological Chemistry, vol. 269(8); pp. 5489-5492 (1994).
Kitamura et al., “Chemical Engineering of the Monoclonal Antibody A7 by Polyethylene Glycol for Targeting Cancer Chemotherapy,”Cancer Research, 51:4310-4315 (1991).
Santa Cruz Biotechnology Inc datasheet for EphB4 (H-200): sc-5536.
Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4.
Dermer, (Bio/Technology, 1994, 12:320).
Gura, (Science, 1997, 278:1041-1042).
Sola et al. (Journal of Virology, May 1998, 3762-3772).
Xia et al. (Clinical Cancer Research, Jun. 2005, 11(12): 4305-4315).
Seffernick et al., “Melamine Deaminase and Atrazine Chlorohydrolase: 98 Percent Identical but Functionally Different”, Journal of Bacteriology, vol. 183(8), pp. 2405-2410 (2001).
Bennett et al., “Extracellular Domain-IgG Fusion Proteins for Three Human Natriuretic Peptide Receptors,” The Journal of Biological Chemistry, vol. 266(34), pp. 23060-23067 (1991).
Kiessig et al., “Application of a green fluorescent fusion protein to study protein-protein interactions by electrophoretic methods,” Electrophoresis, vol. 22, pp. 1428-1435 (2001).
Perrin et al., “Expression, Purification, and Characterization of a Soluble Form of the First Extracellular Domain of the Human Type 1 Corticotropin Releasing Factor Receptor,” The Journal of Biological Chemistry, vol. 276(34), pp. 31528-31534 (2001).
Adams, R.H., et al., “Eph Receptors and Ephrin Ligands: Essential Mediators of Vascular Development,”Trends. Cardiovasc. Med., 10:183-188 (2000).
Adams, R.H., et al., “Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis,” Genes Dev. 13:295-306 (1999).
Andres, A. C. et al., “Expression of two novel eph-related receptor protein tyrosine kinases in mammary gland development and carcinogenesis,”Oncogene, 9:1461-1467 (1994).
Asahara, T. et al., “Isolation of Putative Progenitor Endothelial Cells for Angiogenesis,”Science, 275:964-967 (1997).
Batlle, E., et al., “EphB receptor activity suppresses colorectal cancer progression,”Nature, 435(23):1126-1130 (2005).
Bennett, B. D. et al., “Molecular cloning of a ligand for the Eph-related receptor protein-tyrosine kinase Htk,”Proc. Natl. Acad. Sci. USA, 92:1866-1870 (1995).
Bennett, B.D., et al., “Cloning and Characterization ofHTK, a Novel Transmembrane Tyrosine Kinase of the EPH Subfamily,”The Journal of Biological Chemistry, 269(19): 14211-14218 (1994).
Berclaz, G., et al., “Activation of the receptor protein tyrosine kinase EphB4 in endometrial hyperplasia and endometrial carcinoma,” Ann. Oncol., 14:220-226 (2003).
Berclaz, G., et al., “Expression of the receptor protein tyrosine kinase myk-1/htk in normal and malignant mammary epithelium,” Biochem Biophys Res Commun., 24;226:869-875 (1996).
Bergemann, A. D. et al., “ELF-2, a New Member of the Eph Ligand Family Is Segmentally Expressed in Mouse Embryos in the Region of the Hindbrain and Newly Forming Somites,”Molecular and Cellular Biology, 15(9):4921-4929 (1995).
Bos et al., “PD153035, a Tyrosine Kinase Inhibitor, Prevents Epidermal Growth Factor Receptor Activation and Inhibitors Growth of Cancer Cells in a Receptor Number-dependent Manner,”Clinical Cancer Research, 3:2099-2106 (1997).
Boyd, W.A., et al., “Isolation and Characterization of a Novel Receptor-type Protein Tyrosine Kinase (hek) from a Human Pre-B Cell Line,”The Journal of Biological Chemistry, 267(5):3262-3267 (1992).
Brambilla, R., et al., “Membrane-bound LERK2 ligand can signal through three different Eph-related receptor tyrosine kinases,” EMBO J., 14:3116-3126 (1995).
Brehmer e
Gill Parkash
Kertesz Nathalie
Krasnoperov Valery
Reddy Ramachandra
Zozulya Sergey
Aeder Sean E
Ropes & Gray LLP
VasGene Therapeutics, Inc.
LandOfFree
Polypeptide compounds for inhibiting angiogenesis and tumor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polypeptide compounds for inhibiting angiogenesis and tumor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polypeptide compounds for inhibiting angiogenesis and tumor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2620851